

Envigo appoints Patricia Henahan as new Chief Financial Officer

10 June 2016 | News

Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania



Singapore: Giant drug makers like Aurobindo Pharma, Cadila and Mcleods Pharmaceuticals are among 39 <u>Indian</u> firms that have been blacklisted by <u>Vietnam</u> for quality standard violations. The country's regulators have also banned companies from Bangladesh and South Korea on its website, but has not specified the reason for the ban.

The list of companies in the Drug Regulatory Authority of <u>Vietnam</u>'s black list for regulatory non-compliance in 2014 included companies such as Strides Arcolab Ltd, Medley Pharmaceuticals Ltd, Marck Biosciences Ltd, Marksans Pharma Ltd and Umedica Laboratories Pvt. Ltd.

Antibiotics made by Aurobindo and Mcleod, and Cadila's anti-rabies vaccine Lyssavac have been banned. Lyssavac, Cadila's anti-rabies vaccine was also banned by World Health Organisation in January this year. A representative of a banned company casted doubt on the samples collected and said that problem is with the retail stores who do not follow proper storage methods.

Industry analysts estimate that the ban will affect the performance of the Indian pharma sector to a large extent. A similar ban imposed by Vietnam imposed on 45 Indian pharmaceutical products to Vietnamese market. According to livemint, who relied on official commerce ministry data, exports fell 12% to \$146 million in 2015-16 from \$165 million in the previous fiscal year.

"Certain storage conditions need to be maintained for some products. Our control samples are absolutely fine. The products were banned on the basis of one sample. We will approach the Vietnamese regulator soon," a senior executive of a blacklisted company was quoted saying to Economic Times.